BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $412,000 | +34.6% | 4,804 | +26.3% | 0.08% | +22.1% |
| Q3 2021 | $306,000 | -22.5% | 3,804 | -22.4% | 0.07% | -20.9% |
| Q2 2021 | $395,000 | -0.5% | 4,904 | +4.3% | 0.09% | -11.3% |
| Q1 2021 | $397,000 | +5.3% | 4,703 | 0.0% | 0.10% | +1.0% |
| Q4 2020 | $377,000 | -2.3% | 4,703 | -2.1% | 0.10% | -9.4% |
| Q3 2020 | $386,000 | -15.0% | 4,803 | -8.8% | 0.11% | -19.7% |
| Q2 2020 | $454,000 | +6.1% | 5,268 | 0.0% | 0.13% | -9.6% |
| Q1 2020 | $428,000 | -2.7% | 5,268 | 0.0% | 0.15% | +11.5% |
| Q4 2019 | $440,000 | -6.2% | 5,268 | -1.8% | 0.13% | -10.3% |
| Q3 2019 | $469,000 | +3.8% | 5,367 | -2.7% | 0.15% | +0.7% |
| Q2 2019 | $452,000 | -0.7% | 5,517 | -1.5% | 0.14% | -9.9% |
| Q1 2019 | $455,000 | +23.3% | 5,602 | 0.0% | 0.16% | +6.6% |
| Q4 2018 | $369,000 | -14.6% | 5,602 | +0.0% | 0.15% | -6.2% |
| Q3 2018 | $432,000 | +4.3% | 5,601 | 0.0% | 0.16% | -3.0% |
| Q2 2018 | $414,000 | +11.6% | 5,601 | -1.8% | 0.17% | +5.7% |
| Q1 2018 | $371,000 | -5.8% | 5,701 | -6.4% | 0.16% | -5.4% |
| Q4 2017 | $394,000 | +30.0% | 6,092 | +26.3% | 0.17% | +15.3% |
| Q3 2017 | $303,000 | +1.3% | 4,825 | -2.1% | 0.14% | -3.4% |
| Q2 2017 | $299,000 | -2.6% | 4,931 | -16.6% | 0.15% | -3.2% |
| Q1 2017 | $307,000 | -5.8% | 5,911 | -19.7% | 0.15% | -13.0% |
| Q4 2016 | $326,000 | -55.6% | 7,362 | -98.0% | 0.18% | -11.5% |
| Q3 2016 | $734,000 | +66.4% | 374,768 | +3741.0% | 0.20% | -17.7% |
| Q2 2016 | $441,000 | -7.2% | 9,757 | -15.6% | 0.24% | -9.3% |
| Q1 2016 | $475,000 | -54.2% | 11,561 | -57.4% | 0.27% | -56.1% |
| Q4 2015 | $1,036,000 | -41.8% | 27,167 | -49.8% | 0.61% | -47.8% |
| Q3 2015 | $1,779,000 | -33.9% | 54,154 | +40.7% | 1.17% | -29.3% |
| Q2 2015 | $2,692,000 | +7.0% | 38,490 | +4.7% | 1.65% | +6.6% |
| Q1 2015 | $2,517,000 | -4.9% | 36,749 | +1.8% | 1.55% | -4.9% |
| Q4 2014 | $2,647,000 | +3.5% | 36,101 | +1.3% | 1.63% | -0.9% |
| Q3 2014 | $2,557,000 | +0.7% | 35,628 | +1.5% | 1.65% | +4.1% |
| Q2 2014 | $2,539,000 | -1.7% | 35,112 | +0.0% | 1.58% | +0.6% |
| Q1 2014 | $2,583,000 | +8.0% | 35,111 | +2.2% | 1.57% | +7.7% |
| Q4 2013 | $2,391,000 | +2.5% | 34,372 | -3.2% | 1.46% | -4.0% |
| Q3 2013 | $2,333,000 | -54.2% | 35,520 | -98.6% | 1.52% | -11.2% |
| Q2 2013 | $5,090,000 | – | 2,582,074 | – | 1.71% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |